id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S14329 R56694 |
Ishikawa (Controls unexposed, disease free), 2023 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
1.98 [0.78;5.02] C excluded (control group) |
5/44 4,519/74,213 | 4,524 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14330 R56696 |
Ishikawa (Controls unexposed, sick), 2023 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 1.69 [0.65;4.42] C | 5/44 71/1,007 | 76 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14425 R57257 |
Mito, 2019 | Major anomalies _ morphologic abnormalities | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 0.89 [0.17;4.57] | 2/48 6/129 | 8 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13989 R54933 |
Weber-Schoendorfer, 2008 | Major birth defects (chromosomal anomalies/syndromes excluded) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.63 [0.21;12.82] C | 1/32 14/723 | 15 | 32 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.46 [0.68;3.15] | 99 | 124 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 14329